ADC Therapeutics SA (ADCT) is a publicly traded Healthcare sector company. As of July 5, 2026, ADCT trades at $1.19 with a market cap of $151.36M and a P/E ratio of -1.20. ADCT moved +6.14% today. Year to date, ADCT is -66.00%; over the trailing twelve months it is -57.50%. Its 52-week range spans $0.78 to $4.98. Analyst consensus is buy with an average price target of $5.67. Rallies surfaces ADCT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks hedge fund and 13F ownership for ADCT, including fund holders, share counts, and position changes when data is available.
| Metric | Value |
|---|---|
| Price | $1.19 |
| Market Cap | $151.36M |
| P/E Ratio | -1.20 |
| EPS | $-0.99 |
| Dividend Yield | 0.00% |
| 52-Week High | $4.98 |
| 52-Week Low | $0.78 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $79.17M |
| Net Income | $-136.99M |
| Gross Margin | 0.00% |
4 analysts cover ADCT: 0 strong buy, 2 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $5.67.